Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 4/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | SCD | O00767 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.35 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.35 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 5/20 | 0.35 |
| ▸ | CTSA | P10619 | 2/20 | 0.35 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL952647 | 0.94 | PLK1 (0.37) | PLK1SCDFFAR1PPARDCTSA | |
| SCHEMBL953838 | 0.88 | CDC7 (0.44) | PLK1ROCK2SCDFFAR1PPARD | |
| SCHEMBL953256 | 0.86 | CDC7 (0.44) | PLK1SCDPPARD | |
| SCHEMBL955283 | 0.84 | CDC7 (0.36) | PLK1CTSAF2RL3 | |
| SCHEMBL956260 | 0.82 | PDE10A (0.33) | FFAR1PPARDF2RL3 | |
| SCHEMBL957485 | 0.82 | SCD (0.40) | ROCK2SCDFFAR1PPARD | |
| SCHEMBL957103 | 0.79 | CDC7 (0.42) | SCDFFAR1 | |
| SCHEMBL951783 | 0.79 | CDC7 (0.43) | SCDPPARD | |
| SCHEMBL955503 | 0.79 | CDC7 (0.36) | PLK1 | |
| SCHEMBL953922 | 0.78 | MAP4K1 (0.36) | CTSAF2RL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139589-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9090601-B2 | Thiazole derivatives | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| EP-2391619-A1 | HETEROARYLS AND THEIR USE AS PI3K INHIBITORS | Millennium Pharmaceuticals, Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| US-20110003807-A1 | Thiazole derivatives | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110003806-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| WO-2010090716-A1 | HETEROARYLS AND THEIR USE AS PI3K INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003807-A1 | Thiazole derivatives | MTOR, RICTOR, AKT2 | PLK1 558/4885ROCK2 947/4885SCD 2732/4885 |
| US-20110003806-A1 | Heteroaryls and uses thereof | RICTOR, MTOR, AKT1S1 | PLK1 1770/4885ROCK2 294/4885SCD 914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.